ATE186913T1 - 17-substituierte steroide, verwendbar bei behandlung von krebs - Google Patents

17-substituierte steroide, verwendbar bei behandlung von krebs

Info

Publication number: ATE186913T1
Authority: AT; Austria
Prior art keywords: carbon atoms; beta; hydrogen atom; pyridyl; alkyl
Prior art date: 1992-03-31

Application number

AT93906670T

Other languages

English (en)

Inventor

Susan Elaine Barrie

Michael Jarman

Gerard Andrew Potter

Original Assignee

Btg Int Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-03-31

Filing date

1993-03-15

Publication date

1999-12-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26300621&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE186913(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-03-31 Priority claimed from GB929207057A external-priority patent/GB9207057D0/en

1992-11-27 Priority claimed from GB929224880A external-priority patent/GB9224880D0/en

1993-03-15 Application filed by Btg Int Ltd filed Critical Btg Int Ltd

1999-12-15 Application granted granted Critical

1999-12-15 Publication of ATE186913T1 publication Critical patent/ATE186913T1/de

Links

150000003431 steroids Chemical class 0.000 title abstract 2
206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
125000004432 carbon atom Chemical group C* 0.000 abstract 6
125000000217 alkyl group Chemical group 0.000 abstract 5
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
230000001419 dependent effect Effects 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
206010006187 Breast cancer Diseases 0.000 abstract 1
208000026310 Breast neoplasm Diseases 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
206010060862 Prostate cancer Diseases 0.000 abstract 1
208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 1
239000003098 androgen Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000000262 estrogen Substances 0.000 abstract 1
125000005843 halogen group Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
125000004043 oxo group Chemical group O=* 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT93906670T 1992-03-31 1993-03-15 17-substituierte steroide, verwendbar bei behandlung von krebs ATE186913T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB929207057A GB9207057D0 (en)	1992-03-31	1992-03-31	Steroids
GB929224880A GB9224880D0 (en)	1992-11-27	1992-11-27	Steroids

Publications (1)

Publication Number	Publication Date
ATE186913T1 true ATE186913T1 (de)	1999-12-15

Family

ID=26300621

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93906670T ATE186913T1 (de)	1992-03-31	1993-03-15	17-substituierte steroide, verwendbar bei behandlung von krebs

Country Status (16)

Country	Link
EP (1)	EP0633893B1 (de)
JP (1)	JP2742331B2 (de)
KR (1)	KR100235135B1 (de)
AT (1)	ATE186913T1 (de)
AU (1)	AU668144B2 (de)
CA (1)	CA2132449C (de)
CZ (1)	CZ287434B6 (de)
DE (2)	DE69327096T2 (de)
DK (1)	DK0633893T3 (de)
ES (1)	ES2138618T3 (de)
GB (1)	GB2265624B (de)
IL (1)	IL105078A (de)
LU (1)	LU91911I2 (de)
MX (1)	MX9301525A (de)
NZ (1)	NZ249911A (de)
WO (1)	WO1993020097A1 (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU676088B2 (en) *	1993-09-30	1997-02-27	British Technology Group Limited	Synthesis of 17-(3-pyridyl) steroids
NZ274694A (en) *	1993-10-27	1998-01-26	Merrell Pharma Inc	Androst-16-en-3-ol derivatives having a (thi)azacycloalkyl group substituted by amino at c-17 or by unsubstituted pyrrole, thienyl or furanyl
PE20020596A1 (es)	2000-11-17	2002-08-13	Takeda Chemical Industries Ltd	Derivados de imidazol, metodos de produccion e intermediarios del mismo
ATE502030T1 (de)	2000-11-20	2011-04-15	Takeda Pharmaceutical	Imidazolderivate, verfahren zu deren herstellung und deren verwendung
CA2431171A1 (en)	2000-12-08	2002-06-13	Takeda Chemical Industries, Ltd.	Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
JP2005516927A (ja) *	2001-12-13	2005-06-09	アボット・ラボラトリーズ	癌治療用のキナーゼ阻害剤としての３−（フェニル−アルコキシ）−５−（フェニル）−ピリジン誘導体および関連化合物
US8569275B2 (en)	2002-08-28	2013-10-29	Harbor Therapeutics, Inc.	Steroids having 7-oxgen and 17-heteroaryl substitution
EP2298315A1 (de) *	2002-08-28	2011-03-23	Harbor BioSciences, Inc.	Therapeutische Behandlungsmethoden
GB0418900D0 (en)	2004-08-24	2004-09-29	Btg Int Ltd	Novel salt forms
EP2428519B1 (de) *	2004-08-24	2015-01-21	BTG International Limited	Zusammenstellung zur Herstellung von 17-Vinyl-Triflate als Zwischenprodukte
DE102006008074B4 (de) *	2006-02-22	2013-08-14	RUHR-UNIVERSITäT BOCHUM	Behandlung von Krebs mit Geruchsrezeptor-Liganden
EP2425874A3 (de) *	2006-08-25	2013-05-15	Cougar Biotechnology, Inc.	Verwendung von einer Vitamin D Verbindung und eines zusätzlichen therapeutischen Mittel in der Behandlung von Krebs
US20080051380A1 (en)	2006-08-25	2008-02-28	Auerbach Alan H	Methods and compositions for treating cancer
PL2478907T3 (pl)	2006-08-25	2021-10-25	Janssen Oncology, Inc.	Kompozycje do leczenia nowotworu
US20090124587A1 (en) *	2007-07-12	2009-05-14	Auerbach Alan H	METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
US20100048913A1 (en)	2008-03-14	2010-02-25	Angela Brodie	Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
CN102686600A (zh) *	2009-02-05	2012-09-19	托凯药业股份有限公司	甾体cyp17抑制剂/抗雄激素物质的新型药物前体
WO2010149755A1 (en)	2009-06-26	2010-12-29	Novartis Ag	1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
WO2011059969A2 (en) *	2009-11-13	2011-05-19	Tokai Pharmaceuticals, Inc.	Mammalian metabolites of steroids
US20110178065A1 (en) *	2010-01-15	2011-07-21	Biomarin Pharmaceutical Inc.	Novel cyp17 inhibitors
KR101926320B1 (ko)	2010-08-04	2018-12-06	펠피큐어 파마슈티걸즈 아이엔씨	전립선 암종의 치료를 위한 병용 요법
JP2013537210A (ja)	2010-09-16	2013-09-30	ノバルティスアーゲー	１７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
CN102558274B (zh) *	2010-12-08	2014-10-15	深圳万乐药业有限公司	一种适合工业化生产醋酸阿比特龙的合成方法
EP2651916A2 (de) *	2010-12-16	2013-10-23	BioMarin Pharmaceutical Inc.	Steroidale c-17-heteroarylverbindungen als inhibitoren von cyp11b, cyp17 und/oder cyp21
CN102558275A (zh) *	2010-12-20	2012-07-11	天津药物研究院	α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
US9029399B2 (en)	2011-04-28	2015-05-12	Novartis Ag	17α-hydroxylase/C17,20-lyase inhibitors
CN102321142A (zh) *	2011-09-29	2012-01-18	重庆医药工业研究院有限责任公司	一种醋酸阿比特龙晶型及其制备方法
DE102011083725A1 (de) *	2011-09-29	2013-04-04	Bayer Pharma AG	Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
CN104066744B (zh)	2011-10-10	2017-03-22	扎克系统公司	用于制备17‑取代的甾体的方法
CN103059090B (zh) *	2011-10-20	2016-06-22	连云港润众制药有限公司	醋酸阿比特龙草酸盐以及醋酸阿比特龙的纯化方法
HRP20191982T4 (hr)	2011-11-30	2023-01-06	Astrazeneca Ab	Kombinacijsko liječenje raka
CN103172690B (zh) *	2011-12-23	2016-08-24	重庆医药工业研究院有限责任公司	醋酸阿比特龙及其中间体的制备方法
EP2607371A1 (de)	2011-12-23	2013-06-26	Crystal Pharma, S.A.U.	Verfahren zur Herstellung von Abirateron und verwandten Verbindungen
CN103193849B (zh) *	2012-01-04	2016-05-04	连云港润众制药有限公司	一种高纯度醋酸阿比特龙的制备方法
CN103254265B (zh)	2012-02-21	2016-07-13	上海希迈医药科技有限公司	醋酸阿比特龙三氟乙酸盐及其制备方法和应用
CN102627681B (zh) *	2012-03-23	2016-04-13	山东新时代药业有限公司	一种醋酸阿比特龙的制备方法
AU2013204533B2 (en)	2012-04-17	2017-02-02	Astrazeneca Ab	Crystalline forms
EP2841444A4 (de) *	2012-04-23	2015-11-04	Alphora Res Inc	Verfahren zur herstellung von 17-substituierten steroiden
RU2014154009A (ru)	2012-06-06	2016-08-10	Новартис Аг	Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания
CN102731605B (zh) *	2012-06-19	2016-04-13	鲁南制药集团股份有限公司	一种醋酸阿比特龙的纯化方法
PE20150353A1 (es) *	2012-07-10	2015-03-28	Bayer Pharma AG	Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos
WO2014009434A1 (en)	2012-07-11	2014-01-16	Sandoz Ag	Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
WO2014009437A1 (en)	2012-07-11	2014-01-16	Sandoz Ag	Oxidation stability of abiraterone acetate
WO2014009436A1 (en)	2012-07-11	2014-01-16	Sandoz Ag	Nanosuspension of abiraterone acetate
WO2014016830A1 (en) *	2012-07-25	2014-01-30	Mapi Pharma Ltd.	Process and intermediates for the preparation of abiraterone acetate
WO2014058785A1 (en)	2012-10-10	2014-04-17	Novartis Ag	Combination therapy
ITMI20121788A1 (it)	2012-10-22	2014-04-23	Olon Spa	Procedimento per la purificazione di abiraterone acetato
EP2917225A1 (de)	2012-11-09	2015-09-16	Synthon BV	Verfahren zur herstellung von abirateron-3-acetat
WO2014071983A1 (en)	2012-11-09	2014-05-15	Synthon Bv	Process for making the 17-triflate intermediate of abiraterone-3-acetate
TWI570131B (zh) *	2012-11-13	2017-02-11	賽克系統公司	製備１７－經取代類固醇之方法
WO2014075978A1 (en)	2012-11-16	2014-05-22	Synthon B.V.	Process for the production of abiraterone-3-acetate involving an enol trliflation reaction in the presence of an alkoxy-pyridine compound
CN103059091B (zh) *	2012-11-22	2017-04-19	常州靶点医药科技有限公司	一种避免重金属残留的醋酸阿比特龙的制备方法
CN103864878A (zh) *	2012-12-12	2014-06-18	天津大学	阿比特龙醋酸酯的制备方法
EP2938625B1 (de)	2012-12-31	2018-02-21	Hetero Research Foundation	Verfahren zur herstellung von abirateronacetat
RU2015137617A (ru)	2013-03-14	2017-04-18	Юниверсити Оф Мэриленд, Балтимор Офис Оф Текнолоджи Трансфер	Агенты, подавляющие андрогенные рецепторы, и их применение
CA2902335C (en)	2013-03-14	2021-09-14	Pellficure Pharmaceuticals, Inc.	Novel therapy for prostate carcinoma
PL2792682T3 (pl)	2013-04-19	2017-04-28	Zach System	Sposób wytwarzania stałej postaci octanu abirateronu
US20160176915A1 (en) *	2013-06-24	2016-06-23	Sun Pharmaceutical Industries Limited	Process for preparation of abiraterone acetate
CA2919484C (en)	2013-07-29	2021-05-11	Industriale Chimica S.R.L.	Process for the preparation of abiraterone or abiraterone acetate
ITMI20131861A1 (it) *	2013-11-08	2015-05-09	Ind Chimica Srl	Processo per la preparazione di abiraterone e abiraterone acetato
US9650410B2 (en)	2013-07-29	2017-05-16	Industriale Chimica S.R.L.	Process for the preparation of abiraterone and abiraterone acetate
CN105636594A (zh)	2013-08-12	2016-06-01	托凯药业股份有限公司	使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
CN104558091B (zh) *	2013-10-16	2017-07-28	天津金耀集团有限公司	一种醋酸阿比特龙的合成方法
WO2015114518A2 (en) *	2014-01-28	2015-08-06	Olon S.P.A.	Procedure for the preparation of abiraterone acetate and intermediates thereof
CN103965282B (zh)	2014-04-21	2016-01-20	武汉百科药物开发有限公司	一种醋酸阿比特龙的制备方法
US9315541B2 (en)	2014-05-20	2016-04-19	Olon S.P.A.	Process for the preparation of unsaturated trifluoromethanesulfonate steroid derivatives
EP3160450A1 (de)	2014-06-30	2017-05-03	Galenicum Health S.L.	Stabile pharmazeutische zusammensetzungen in form von tabletten mit unmittelbarer freisetzung
CZ2014475A3 (cs)	2014-07-09	2016-01-20	Zentiva, K.S.	Způsob přípravy Abirateron acetátu o vysoké čistotě aplikovatelný v průmyslovém měřítku
WO2016040896A1 (en)	2014-09-12	2016-03-17	Pellficure Pharmaceuticals, Inc.	Compositions and methods for treatment of prostate carcinoma
HUE054935T2 (hu)	2014-12-05	2021-10-28	Aragon Pharmaceuticals Inc	Rákellenes készítmények
SG11201704267VA (en)	2014-12-05	2017-06-29	Aragon Pharmaceuticals Inc	Anticancer compositions
US10722527B2 (en)	2015-04-10	2020-07-28	Capsugel Belgium Nv	Abiraterone acetate lipid formulations
CN108541255B (zh) *	2016-02-02	2019-06-14	深圳市塔吉瑞生物医药有限公司	一种甾体类化合物及包含该化合物的组合物及其用途
CA3024872A1 (en)	2016-06-03	2017-12-07	Aragon Pharmaceuticals, Inc.	Anticancer compositions
UA124972C2 (uk)	2016-07-29	2021-12-22	Янссен Фармацевтика Нв	Способи лікування раку передміхурової залози
AU2017350690A1 (en)	2016-10-24	2019-06-13	Pellficure Pharmaceuticals Inc.	Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione
CA3098208A1 (en)	2018-04-26	2019-10-31	Synthon B.V.	Tablet compositions comprising abiraterone acetate
HU231297B1 (hu)	2018-07-31	2022-09-28	Richter Gedeon Nyrt	Stabil gyógyszerkészítmények és eljárás az előállításukra
CN110272465A (zh) *	2019-07-15	2019-09-24	成都贝诺科成生物科技有限公司	阿比特龙衍生物、其制备方法与应用
TWI857119B (zh)	2019-08-08	2024-10-01	香港商來凱有限公司	治療癌症之方法
EP3854384A1 (de)	2020-01-27	2021-07-28	Adamed Pharma S.A.	Pharmazeutische formulierung, die abirateronacetat umfasst
TWI905184B (zh)	2020-05-08	2025-11-21	比利時商健生藥品公司	用醋酸阿比特龍和尼拉帕尼之組合治療前列腺癌
EP3944860A1 (de)	2020-07-30	2022-02-02	Galenicum Health S.L.U.	Abirateron zur verwendung in einem verfahren zur behandlung von krebs
CA3243120A1 (en)	2022-02-04	2023-08-10	Janssen Pharmaceutica Nv	Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and changes in hormone receptor function (HRF)
WO2023155846A1 (zh) *	2022-02-18	2023-08-24	上海醇健医药技术有限公司	17-吡啶基-10α-甲基-甾体衍生物及中间体化合物、其制备方法、其用途、以及其药物组合物
CN116589519A (zh) *	2023-05-17	2023-08-15	江西川奇药业有限公司	一种醋酸阿比特龙及其中间产物的合成方法
WO2025027138A1 (en)	2023-08-02	2025-02-06	Janssen Pharmaceutica Nv	Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA882717B (en) *	1987-04-22	1988-10-17	Merrell Dow Pharmaceuticals Inc.	17beta-(cyclopropylamino)-androst-5-eb-3beta-ol and related compounds useful as c17-20 lyase inhibitors
US4966898A (en) *	1989-08-15	1990-10-30	Merrell Dow Pharmaceuticals Inc.	4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors

1993
- 1993-03-15 CA CA002132449A patent/CA2132449C/en not_active Expired - Lifetime
- 1993-03-15 ES ES93906670T patent/ES2138618T3/es not_active Expired - Lifetime
- 1993-03-15 AT AT93906670T patent/ATE186913T1/de active
- 1993-03-15 AU AU37584/93A patent/AU668144B2/en not_active Expired
- 1993-03-15 CZ CZ19942337A patent/CZ287434B6/cs not_active IP Right Cessation
- 1993-03-15 WO PCT/GB1993/000531 patent/WO1993020097A1/en not_active Ceased
- 1993-03-15 GB GB9305269A patent/GB2265624B/en not_active Expired - Lifetime
- 1993-03-15 KR KR1019940703426A patent/KR100235135B1/ko not_active Expired - Lifetime
- 1993-03-15 JP JP5517187A patent/JP2742331B2/ja not_active Expired - Lifetime
- 1993-03-15 NZ NZ249911A patent/NZ249911A/en not_active IP Right Cessation
- 1993-03-15 DE DE69327096T patent/DE69327096T2/de not_active Expired - Lifetime
- 1993-03-15 EP EP93906670A patent/EP0633893B1/de not_active Expired - Lifetime
- 1993-03-15 DK DK93906670T patent/DK0633893T3/da active
- 1993-03-16 IL IL105078A patent/IL105078A/xx active Protection Beyond IP Right Term
- 1993-03-18 MX MX9301525A patent/MX9301525A/es active IP Right Grant
2011
- 2011-12-07 LU LU91911C patent/LU91911I2/fr unknown
2012
- 2012-01-12 DE DE201212000012 patent/DE122012000012I1/de active Pending

Also Published As

Publication number	Publication date
DE69327096D1 (de)	1999-12-30
ES2138618T3 (es)	2000-01-16
GB2265624A (en)	1993-10-06
CZ287434B6 (en)	2000-11-15
EP0633893A1 (de)	1995-01-18
NZ249911A (en)	1996-06-25
DE122012000012I1 (de)	2012-06-14
CA2132449A1 (en)	1993-10-14
GB2265624B (en)	1995-04-19
EP0633893B1 (de)	1999-11-24
CZ233794A3 (en)	1995-02-15
DE69327096T2 (de)	2000-06-21
IL105078A (en)	1997-11-20
MX9301525A (es)	1994-02-28
JPH07505377A (ja)	1995-06-15
DK0633893T3 (da)	2000-04-17
AU668144B2 (en)	1996-04-26
GB9305269D0 (en)	1993-05-05
WO1993020097A1 (en)	1993-10-14
CA2132449C (en)	2002-09-10
KR950700923A (ko)	1995-02-20
IL105078A0 (en)	1993-07-08
KR100235135B1 (ko)	2000-01-15
LU91911I2 (fr)	2012-02-07
AU3758493A (en)	1993-11-08
JP2742331B2 (ja)	1998-04-22

Publication	Publication Date	Title
ATE186913T1 (de)	1999-12-15	17-substituierte steroide, verwendbar bei behandlung von krebs
RU2210574C2 (ru)	2003-08-20	Очищенные стероидсульфаматные соединения, эстрон-сульфаматы
KR910004651A (ko)	1991-03-29	5α-환원효소 억제제로서의 17β-아실-4-아자-5α-안드로스트-1-엔-3-온
NO975608D0 (no)	1997-12-04	Neuroaktive steroider av androstan og pregnan serier
SE9100342D0 (sv)	1991-02-04	Novel steroid esters
DE69131345D1 (de)	1999-07-22	Behandlung von pruritus mit estern und amiden
KR950701527A (ko)	1995-04-28	테스토스테론 5α 환원효소 활성 저해제(INHIBITORS OF TESTOSTERONE 5α-REDUCTASE ACTIVITY)
ATE128983T1 (de)	1995-10-15	17-spirofuran-3'-yliden steroide.
PT88648A (pt)	1988-10-01	Process for the preparation of new androstane 17-carboxylic acid esters and a pharmaceutical composition containing same
AP9801431A0 (en)	1998-12-31	Steroid bisphosphonates.
DE2960689D1 (en)	1981-11-19	Fluorene and fluoranthene derivatives, process for their preparation and their therapeutic application
US3637668A (en)	1972-01-25	N-substituted 4-aminosteroids
IT1154735B (it)	1987-01-21	Derivati d'amino-14 steroidi e procedimento per la loro preparazione
KR940701260A (ko)	1994-05-28	스테로이드 함유 안구용 약제조성물, 이것을 녹내장 치료에 사용하는 방법 및 이것의 제조방법
DE60014096D1 (de)	2004-10-28	Durch 11-beta-aryl-17,17-spirothiolan substituierte steroide
WO2004093852A3 (en)	2004-12-23	Use of steroid derivatives for the treatment of angiotensin ii related disease e.g. cardiovascular and proliferative disorders
WO1990015067A3 (fr)	1991-01-24	NOUVEAUX PROCEDES D'OBTENTION DE 6-METHYL 19-NOR STEROIDES ET LEUR CONVERSION EN 19-NOR PREGNADIENES 17α-SUBSTITUES
GR22382B (el)	1961-10-21	Βελτιωσεις εις η σχετικως προς μεθοδους παρασκευης νεων στεροειδων ενωσεων.
JPS51149258A (en)	1976-12-22	A process for preparing steroid derivatives
GB1113184A (en)	1968-05-08	The manufacture of 10ª-steroids
JO1713B1 (en)	1992-12-15	Modern fatty acid esters
GB826362A (en)	1960-01-06	Steroid compounds and therapeutic compositions containing them
PT75900A (de)	1982-12-01	Neue oxyme von 3'''-dehydro-cardenolid-trididitoxosiden verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB1063661A (en)	1967-03-30	Improvements in or relating to steroids and the manufacture thereof
CH606112A5 (en)	1978-10-13	Hormonally active D-homosteroids